Markers of acute inflammation in assessing and managing lower respiratory tract infections: Focus on procalcitonin

Clinical Microbiology and Infection

Volumn 12, Issue SUPPL. 9, 2006, Pages 8-16

  Muller B ^a   Prat, C ^b  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

Author keywords

Antibiotics; Procalcitonin; Respiratory tract infection

Indexed keywords

ANTIBIOTIC AGENT; BIOLOGICAL MARKER; C REACTIVE PROTEIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; NEOPTERIN; PROCALCITONIN; STEROID; TUMOR NECROSIS FACTOR ALPHA;

BACTERIAL ENDOCARDITIS; BACTERIAL INFECTION; BACTERIUM CULTURE; CASE MANAGEMENT; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ASSESSMENT; COMMUNITY ACQUIRED PNEUMONIA; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE COURSE; DISEASE MARKER; DRUG USE; EARLY DIAGNOSIS; FALSE NEGATIVE RESULT; FALSE POSITIVE RESULT; GENE EXPRESSION; HUMAN; INFLAMMATION; LEGIONELLA; LOWER RESPIRATORY TRACT INFECTION; MALARIA; MENINGITIS; MULTIDRUG RESISTANCE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PANCREATITIS; PATHOPHYSIOLOGY; PNEUMOCYSTIS JIROVECI; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; REFERENCE VALUE; RESPIRATORY FAILURE; RESPIRATORY TRACT INFECTION; REVIEW; SENSITIVITY AND SPECIFICITY; SEPSIS; SEPTIC SHOCK; STREPTOCOCCUS PNEUMONIAE; VENTILATOR ASSOCIATED PNEUMONIA;

EID: 33845440733     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2006.01654.x     Document Type: Review

References (44)

1. Kollef MH, Shorr A, Tabak YP, Gupta V, Liu LZ, Johannes RS. Epidemiology and outcomes of health-care-associated pneumonia: Results from a large US database of culture-positive pneumonia. Chest 2005; 128: 3854-3862.
2. Steinman MA, Gonzales R, Linder JA, Landefeld CS. Changing use of antibiotics in community-based outpatient practice, 1991-1999. Ann Intern Med 2003; 138: 525-533.
3. Mainous AG 3rd, Hueston WJ, Davis MP, Pearson WS. Trends in antimicrobial prescribing for bronchitis and upper respiratory infections among adults and children. Am J Public Health 2003; 93: 1910-1914.
4. Roumie CL, Halasa NB, Grijalva CG et al. Trends in antibiotic prescribing for adults in the United States-1995 to 2002. J Gen Intern Med 2005; 20: 697-702.
5. Dominguez J, Blanco S, Rodrigo C et al. Usefulness of urinary antigen detection by an immunochromatographic test for diagnosis of pneumococcal pneumonia in children. J Clin Microbiol 2003; 41: 2161-2163.
6. Fine MJ, Auble TE, Yealy DM et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 1997; 336: 243-250.
7. Dahmer MK, Randolph A, Vitali S, Quasney MW. Genetic polymorphisms in sepsis. Pediatr Crit Care Med 2005; 6 (3 suppl): S61-S73.
8. Waterer GW, Quasney MW, Cantor RM, Wunderink RG. Septic shock and respiratory failure in community-acquired pneumonia have different TNF polymorphism associations. Am J Respir Crit Care Med 2001; 163: 1599-1604.
9. Dehoux MS, Boutten A, Ostinelli J et al. Compartmentalized cytokine production within the human lung in unilateral pneumonia. Am J Respir Crit Care Med 1994; 150: 710-716.
10. Becker KL, Nylen ES, White JC, Muller B, Snider RH Jr. Clinical review 167: Procalcitonin and the calcitonin gene family of peptides in inflammation, infection, and sepsis: A journey from calcitonin back to its precursors. J Clin Endocrinol Metab 2004; 89: 1512-1525.
11. Luna CM. C-reactive protein in pneumonia: Let me try again. Chest 2004; 125: 1192-1195.
12. Jaye DL, Waites KB. Clinical applications of C-reactive protein in pediatrics. Pediatr Infect Dis J 1997; 16: 735-746.
13. Almirall J, Bolibar I, Toran P et al. Contribution of C-reactive protein to the diagnosis and assessment of severity of community-acquired pneumonia. Chest 2004; 125: 1335-1342.
14. Blau N, Schoedon G, Curtius HC. Biosynthesis and significance of neopterin in the immune system. Eur J Cancer Clin Oncol 1989; 25: 603-605.
15. Assicot M, Gendrel D, Carsin H, Raymond J, Guilbaud J, Bohuon C. High serum procalcitonin concentrations in patients with sepsis and infection. Lancet 1993; 341: 515-518.
16. Müller B, Becker KL, Schachinger H et al. Calcitonin precursors are reliable markers of sepsis in a medical intensive care unit. Crit Care Med 2000; 28: 977-983.
17. Linscheid P, Seboek D, Nylen ES et al. In vitro and in vivo calcitonin I gene expression in parenchymal cells: A novel product of human adipose tissue. Endocrinology 2003; 144: 5578-5584.
18. Müller B, White JC, Nylen ES, Snider RH, Becker KL, Habener JF. Ubiquitous expression of the calcitonin-I gene in multiple tissues in response to sepsis. J Clin Endocrinol Metab 2001; 86: 396-404.
19. Linscheid P, Seboek D, Schaer DJ, Zulewski H, Keller U, Müller B. Expression and secretion of procalcitonin and calcitonin gene-related peptide by adherent monocytes and by macrophage-activated adipocytes. Crit Care Med 2004; 32: 1715-1721.
20. Nylen ES, Whang KT, Snider RH Jr, Steinwald PM, White JC, Becker KL. Mortality is increased by procalcitonin and decreased by an antiserum reactive to procalcitonin in experimental sepsis. Crit Care Med 1998; 26: 1001-1006.
21. Wagner KE, Martinez JM, Vath SD et al. Early immunoneutralization of calcitonin precursors attenuates the adverse physiologic response to sepsis in pigs. Crit Care Med 2002; 30: 2313-2321.
22. Becker KL, Nylen ES, Snider RH, Muller B, White JC. Immunoneutralization of procalcitonin as therapy of sepsis. J Endotoxin Res 2003; 9: 367-374.
23. Nylen ES, Müller Muller B, Becker KL, Snyder RH. The future diagnostic role of procalcitonin levels: The need for improved sensitivity. Clin Infect Dis 2003; 36: 823-824.
24. Simon L, Gauvin F, Amre DK, Saint-Louis P, Lacroix J. Serum procalcitonin and C-reactive protein levels as markers of bacterial infection: A systematic review and meta-analysis. Clin Infect Dis 2004; 39: 206-217.
25. Christ-Crain M, Jaccard-Stolz D, Bingisser R et al. Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections: Cluster-randomised, single-blinded intervention trial. Lancet 2004; 363: 600-607.
26. Müller B, Peri G, Doni A et al. High circulating levels of the IL-1 type II decoy receptor in critically ill patients with sepsis: association of high decoy receptor levels with glucocorticoid administration. J Leukoc Biol 2002; 72: 643-649.
27. Stolz D, Christ-Crain M, Bingisser R et al. Antibiotic treatment of exacerbations of COPD: A randomized, controlled trial comparing procalcitonin-guidance with standard therapy. Chest 2006; in press.
28. Christ-Crain M, Stolz D, Bingisser R et al. Procalcitonin for discontinuation of antibiotic therapy in community-acquired pneumonia-a randomized trial. Am J Respir Crit Care Med 2006; 174: 84-93.
29. Luyt CE, Guerin V, Combes A et al. Procalcitonin kinetics as a prognostic marker of ventilator-associated pneumonia. Am J Respir Crit Care Med 2005; 171: 48-53.
30. Boussekey N, Leroy O, Georges H, Devos P, d'Escrivan T, Guery B. Diagnostic and prognostic values of admission procalcitonin levels in community-acquired pneumonia in an intensive care unit. Infection 2005; 33: 257-263.
31. Briel M, Christ-Crain M, Young J et al. Procalcitonin-guided antibiotic use versus a standard approach for acute respiratory tract infections in primary care: Study protocol for a randomised controlled trial and baseline characteristics of participating general practitioners [ISRCTN73182671]. BMC Fam Pract 2005; 6: 34-42.
32. Prat C, Dominguez J, Rodrigo C et al. Procalcitonin, C-reactive protein and leukocyte count in children with lower respiratory tract infection. Pediatr Infect Dis J 2003; 22: 963-968.
33. Prat C, Dominguez J, Andreo F et al. Procalcitonin and neopterin correlation with aetiology and severity of pneumonia. J Infect 2006; 52: 169-177.
34. Christ-Crain M, Müller B. Procalcitonin in bacterial infections-hype, hope, more or less? Swissmedwkly 2005; 135: 451-460.
35. Mueller C, Huber R, Laifer G, Mueller B, Buerkle G, Perruchoud AP. Procalcitonin and the early diagnosis of infective endocarditis. Circulation 2004; 109: 1707-1710.
36. Tullus K, Fituri O, Linne T et al. Urine interleukin-6 and interleukin-8 in children with acute pyelonephritis, in relation to DMSA scintigraphy in the acute phase and at 1-year follow-up. Pediatr Radiol 1994; 24: 513-515.
37. Benador N, Siegrist CA, Gendrel D et al. Procalcitonin is a marker of severity of renal lesions in pyelonephritis. Pediatrics 1998; 102: 1422-1425.
38. Marc E, Menager C, Moulin F et al. Procalcitonin and viral meningitis: reduction of unnecessary antibiotics by measurement during an outbreak. Arch Pediatr 2002; 9: 358-364.
39. Dornbusch HJ, Strenger V, Kerbl R et al. Procalcitonin and C-reactive protein do not discriminate between febrile reaction to anti-T-lymphocyte antibodies and Gram-negative sepsis. Bone Marrow Transplant 2003; 32: 941-945.
40. Petrikkos GL, Christofilopoulou SA, Tentolouris NK, Charvalos EA, Kosmidis CJ, Daikos GL. Value of measuring serum procalcitonin, C-reactive protein, and mannan antigens to distinguish fungal from bacterial infections. Eur J Clin Microbiol Infect Dis 2005; 24: 272-275.
41. Müller B, Becker KL, Kranzlin M et al. Disordered calcium homeostasis of sepsis: Association with calcitonin precursors. Eur J Clin Invest 2000; 30: 823-831.
42. Hoffmann G, Czechowski M, Schloesser M, Schobersberger W. Procalcitonin amplifies inducible nitric oxide synthase gene expression and nitric oxide production in vascular smooth muscle cells. Crit Care Med 2002; 30: 2091-2095.
43. Wiedermann FJ, Kaneider N, Egger P et al. Migration of human monocytes in response to procalcitonin. Crit Care Med 2002; 30: 1112-1117.
44. Monneret G, Arpin M, Venet F et al. Calcitonin gene related peptide and N-procalcitonin modulate CD11b upregulation in lipopolysaccharide activated monocytes and neutrophils. Intensive Care Med 2003; 29: 923-928.